Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)

The Technology Development Research for Establishing Feasibility and Proof of Concept program is offered by the National Institute of General Medical Sciences, a component of the National Institutes of Health within the U.S. Department of Health and Human Services. NIGMS supports fundamental biomedical research that enhances understanding of biological systems and enables advances in diagnosis, treatment, and prevention of disease. This funding opportunity specifically focuses on early-stage, high-risk, and high-reward technology development projects that have the potential to significantly advance the tools available for biomedical research. The program emphasizes innovation and seeks to catalyze breakthroughs that could transform scientific capabilities across a wide range of biological disciplines. The purpose of this opportunity is to support exploratory research that establishes feasibility and proof of concept for entirely new technologies. These technologies may include laboratory instruments, computational tools, chemical reagents, or engineered biological systems. Projects must be in the earliest conceptual stage and must not include prior proof-of-concept data or preliminary results demonstrating feasibility. The program is designed to encourage bold ideas that may carry a high risk of failure but also a strong potential for long-term impact. Applications that propose incremental improvements, repurposing of existing technologies, or focus on answering specific biological questions are not responsive and will not be considered. Funding under this program is provided through the R21 exploratory/developmental grant mechanism. Applicants may request up to 275000 dollars in direct costs over a maximum project period of two years, with no more than 200000 dollars requested in any single year. Funds are intended to support activities directly related to conceptual development and feasibility testing of new technologies. There is no cost-sharing requirement. Projects should focus exclusively on technology development and may include validation using well-characterized systems, but must not extend to broader biological hypothesis testing or clinical applications. Eligible applicants include a wide range of U.S.-based entities such as institutions of higher education, nonprofit organizations, for-profit companies including small businesses, and government entities at the state, local, or tribal level. Foreign organizations are not eligible to apply, although foreign components within U.S. organizations may be included. Individuals serving as principal investigators must have the appropriate expertise and institutional support to carry out the proposed research. Multiple applications are allowed as long as they are scientifically distinct. Applications must be submitted electronically through Grants.gov using NIH-approved submission systems such as ASSIST or institutional system-to-system solutions. Required application components include standard NIH forms, a detailed research plan, and a mandatory signed letter from the principal investigator confirming compliance with program responsiveness criteria. Applications must strictly follow NIH application instructions, and failure to comply may result in rejection without review. Applicants are encouraged to submit early to allow time for corrections prior to the deadline. Applications are evaluated through the NIH peer review process based on significance, innovation, and feasibility. Reviewers assess whether the proposed technology represents a substantial advance over the current state of the art and whether the approach is rigorous and appropriate for demonstrating feasibility. Additional considerations include the expertise of the research team and the suitability of the institutional environment. Successful applications proceed to a second level of review by an advisory council before funding decisions are made. This funding opportunity followed standard NIH submission cycles with multiple deadlines throughout the year; however, it has been officially terminated earlier than originally planned. The expiration date was revised to May 12, 2026. As of that date, the program is no longer accepting applications. While NIH may allow limited late submissions under special circumstances, applicants are generally directed to monitor the NIH Guide for new or reissued opportunities. The program historically followed recurring cycles, and similar opportunities may be announced in future funding rounds.

Ensure no preliminary data or proof of concept is included; focus strictly on novel untested technology concepts; avoid biological hypothesis testing; clearly articulate innovation beyond current state of the art